Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I

Ken Overturf, Muhsen Al-Dhalimy, Robert Tanguay, Mark Brantly, Ching Nan Ou, Milton Finegold, Markus Grompe

Research output: Contribution to journalArticle

438 Citations (Scopus)

Abstract

Current strategies for hepatic gene therapy are either quantitatively inefficient or suffer from lack of permanent gene expression. We have utilized an animal model of hereditary tyrosinaemia type I (HT1), a recessive liver disease caused by deficiency of fumarylacetoacetate hydrolase (FAH), to determine whether in vivo selection of corrected hepatocytes could improve the efficiency of liver gene transfer. As few as 1,000 transplanted wild- type hepatocytes were able to repopulate mutant liver, demonstrating their strong competitive growth advantage. Mutant hepatocytes corrected in situ by retroviral gene transfer were also positively selected. In mutant animals treated by multiple retrovirus injections >90% of hepatocytes became FAH positive and liver function was restored to normal. Our results demonstrate that in vivo selection is a useful strategy for hepatic gene therapy and may lead to effective treatment of human HT1 by retroviral gene transfer.

Original languageEnglish (US)
Pages (from-to)266-273
Number of pages8
JournalNature Genetics
Volume12
Issue number3
DOIs
StatePublished - Mar 1996

Fingerprint

Tyrosinemias
Genetic Therapy
Hepatocytes
Liver
Genes
Retroviridae
Liver Diseases
Animal Models
Gene Expression
Injections
Growth

ASJC Scopus subject areas

  • Genetics(clinical)
  • Genetics

Cite this

Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. / Overturf, Ken; Al-Dhalimy, Muhsen; Tanguay, Robert; Brantly, Mark; Ou, Ching Nan; Finegold, Milton; Grompe, Markus.

In: Nature Genetics, Vol. 12, No. 3, 03.1996, p. 266-273.

Research output: Contribution to journalArticle

Overturf, Ken ; Al-Dhalimy, Muhsen ; Tanguay, Robert ; Brantly, Mark ; Ou, Ching Nan ; Finegold, Milton ; Grompe, Markus. / Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. In: Nature Genetics. 1996 ; Vol. 12, No. 3. pp. 266-273.
@article{e96563f27697435bb8f4194d12f2378f,
title = "Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I",
abstract = "Current strategies for hepatic gene therapy are either quantitatively inefficient or suffer from lack of permanent gene expression. We have utilized an animal model of hereditary tyrosinaemia type I (HT1), a recessive liver disease caused by deficiency of fumarylacetoacetate hydrolase (FAH), to determine whether in vivo selection of corrected hepatocytes could improve the efficiency of liver gene transfer. As few as 1,000 transplanted wild- type hepatocytes were able to repopulate mutant liver, demonstrating their strong competitive growth advantage. Mutant hepatocytes corrected in situ by retroviral gene transfer were also positively selected. In mutant animals treated by multiple retrovirus injections >90{\%} of hepatocytes became FAH positive and liver function was restored to normal. Our results demonstrate that in vivo selection is a useful strategy for hepatic gene therapy and may lead to effective treatment of human HT1 by retroviral gene transfer.",
author = "Ken Overturf and Muhsen Al-Dhalimy and Robert Tanguay and Mark Brantly and Ou, {Ching Nan} and Milton Finegold and Markus Grompe",
year = "1996",
month = "3",
doi = "10.1038/ng0396-266",
language = "English (US)",
volume = "12",
pages = "266--273",
journal = "Nature Genetics",
issn = "1061-4036",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I

AU - Overturf, Ken

AU - Al-Dhalimy, Muhsen

AU - Tanguay, Robert

AU - Brantly, Mark

AU - Ou, Ching Nan

AU - Finegold, Milton

AU - Grompe, Markus

PY - 1996/3

Y1 - 1996/3

N2 - Current strategies for hepatic gene therapy are either quantitatively inefficient or suffer from lack of permanent gene expression. We have utilized an animal model of hereditary tyrosinaemia type I (HT1), a recessive liver disease caused by deficiency of fumarylacetoacetate hydrolase (FAH), to determine whether in vivo selection of corrected hepatocytes could improve the efficiency of liver gene transfer. As few as 1,000 transplanted wild- type hepatocytes were able to repopulate mutant liver, demonstrating their strong competitive growth advantage. Mutant hepatocytes corrected in situ by retroviral gene transfer were also positively selected. In mutant animals treated by multiple retrovirus injections >90% of hepatocytes became FAH positive and liver function was restored to normal. Our results demonstrate that in vivo selection is a useful strategy for hepatic gene therapy and may lead to effective treatment of human HT1 by retroviral gene transfer.

AB - Current strategies for hepatic gene therapy are either quantitatively inefficient or suffer from lack of permanent gene expression. We have utilized an animal model of hereditary tyrosinaemia type I (HT1), a recessive liver disease caused by deficiency of fumarylacetoacetate hydrolase (FAH), to determine whether in vivo selection of corrected hepatocytes could improve the efficiency of liver gene transfer. As few as 1,000 transplanted wild- type hepatocytes were able to repopulate mutant liver, demonstrating their strong competitive growth advantage. Mutant hepatocytes corrected in situ by retroviral gene transfer were also positively selected. In mutant animals treated by multiple retrovirus injections >90% of hepatocytes became FAH positive and liver function was restored to normal. Our results demonstrate that in vivo selection is a useful strategy for hepatic gene therapy and may lead to effective treatment of human HT1 by retroviral gene transfer.

UR - http://www.scopus.com/inward/record.url?scp=0029875835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029875835&partnerID=8YFLogxK

U2 - 10.1038/ng0396-266

DO - 10.1038/ng0396-266

M3 - Article

C2 - 8589717

AN - SCOPUS:0029875835

VL - 12

SP - 266

EP - 273

JO - Nature Genetics

JF - Nature Genetics

SN - 1061-4036

IS - 3

ER -